Western diet in ApoE-LDLR double-deficient mouse model of atherosclerosis leads to hepatic steatosis, fibrosis, and tumorigenesis

Laboratory Investigation

Volumn 94, Issue 11, 2014, Pages 1273-1282

  Kampschulte, Marian ^a   Stöckl, Christiane ^a   Langheinrich, Alexander C ^b   Althöhn, Ulrike ^a   Bohle, Rainer M ^c   Krombach, Gabriele A ^a   Stieger, Philipp ^d   Churin, Yuri ^a   Kremer, Sandra ^a   Dierkes, Christian ^e   Rath, Timo ^a,f   Roeb, Elke ^a   Roderfeld, Martin ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b BG Chemie   (Germany)

^c SAARLAND UNIVERSITY   (Germany)

^d OTTO VON GUERICKE UNIVERSITY   (Germany)

^e MVZ for Cytology   (Germany)

^f UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA; PROTEIN KINASE B; STAT3 PROTEIN; STRESS ACTIVATED PROTEIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; CONTROLLED STUDY; DIET; DISEASE ASSOCIATION; DYSLIPIDEMIA; FATTY LIVER; GENETIC PREDISPOSITION; HEPATITIS; LIPID METABOLISM; LIVER CARCINOGENESIS; LIVER CELL DAMAGE; LIVER FIBROSIS; LIVER INJURY; LIVER REGENERATION; MALE; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; OXIDATIVE STRESS; PROTEIN ANALYSIS; SIGNAL TRANSDUCTION; VASCULARIZATION; WESTERN DIET; ANIMAL; C57BL MOUSE; COMPLICATION; DISEASE MODEL; GENETICS; KNOCKOUT MOUSE; LIVER CIRRHOSIS; LIVER NEOPLASMS, EXPERIMENTAL; RADIOGRAPHY;

ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; DIET, WESTERN; DISEASE MODELS, ANIMAL; FATTY LIVER; LIPID METABOLISM; LIVER CIRRHOSIS; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTORS, LDL; SIGNAL TRANSDUCTION; X-RAY MICROTOMOGRAPHY;

EID: 84908481540     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2014.112     Document Type: Article

References (38)

1. Ahmed MH, Barakat S, Almobarak AO. Nonalcoholic fatty liver disease and cardiovascular disease: has the time come for cardiologists to be hepatologists? J Obes 2012; 2012: 483135.
2. Armstrong MJ, Houlihan DD, Bentham L, et al. Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort. J Hepatol 2012; 56: 234-240.
3. Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middleaged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011; 140: 124-131.
4. Argo CK, Caldwell SH. Epidemiology and natural history of nonalcoholic steatohepatitis. Clin Liver Dis 2009; 13: 511-531.
5. Hashimoto E, Tokushige K. Prevalence, gender, ethnic variations, and prognosis of NASH. J Gastroenterol 2011; 46(Suppl 1): 63-69.
6. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology 1998; 114: 842-845.
7. Wouters K, van Gorp PJ, Bieghs V, et al. Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis. Hepatology 2008; 48: 474-486.
8. Hijona E, Hijona L, Arenas JI, et al. Inflammatory mediators of hepatic steatosis. Mediators Inflamm 2010; 2010: 837419.
9. Langheinrich AC, Michniewicz A, Bohle RM, et al. Vasa vasorum neovascularization and lesion distribution among different vascular beds in ApoE-/-/LDL-/- double knockout mice. Atherosclerosis 2007; 191: 73-81.
10. He G, Karin M. NF-kappaB and STAT3 - key players in liver inflammation and cancer. Cell Res 2011; 21: 159-168.
11. Luedde T, Schwabe RF. NF-kappaB in the liver-linking injury, fibrosis and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2011; 8: 108-118.
12. Pikarsky E, Ben-Neriah Y. NF-kappaB inhibition: a double-edged sword in cancer? Eur J Cancer 2006; 42: 779-784.
13. Roderfeld M, Rath T, Voswinckel R, et al. Bone marrow transplantation demonstrates medullar origin of CD34+ fibrocytes and ameliorates hepatic fibrosis in Abcb4-/- mice. Hepatology 2010; 51: 267-276.
14. Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol 1995; 19: 1409-1417.
15. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-699.
16. Levene AP, Kudo H, Armstrong MJ, et al. Quantifying hepatic steatosis - more than meets the eye. Histopathology 2012; 60: 971-981.
17. Maeda S, Kamata H, Luo JL, et al. IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 2005; 121: 977-990.
18. Jamall IS, Finelli VN, Que Hee SS. A simple method to determine nanogram levels of 4-hydroxyproline in biological tissues. Anal Biochem 1981; 112: 70-75.
19. Herron GS, Banda MJ, Clark EJ, et al. Secretion of metalloproteinases by stimulated capillary endothelial cells. II. Expression of collagenase and stromelysin activities is regulated by endogenous inhibitors. J Biol Chem 1986; 261: 2814-2818.
20. Pacana T, Fuchs M. The cardiovascular link to nonalcoholic fatty liver disease: a critical analysis. Clin Liver Dis 2012; 16: 599-613.
21. Scorletti E, Calder PC, Byrne CD. Non-alcoholic fatty liver disease and cardiovascular risk: metabolic aspects and novel treatments. Endocrine 2011; 40: 332-343.
22. Ling IF, Estus S. Role of SFRS13A in low-density lipoprotein receptor splicing. Hum Mutat 2010; 31: 702-709.
23. Sazci A, Akpinar G, Aygun C, et al. Association of apolipoprotein E polymorphisms in patients with non-alcoholic steatohepatitis. Dig Dis Sci 2008; 53: 3218-3224.
24. Bieghs V, Van Gorp PJ, Wouters K, et al. LDL receptor knock-out mice are a physiological model particularly vulnerable to study the onset of inflammation in non-alcoholic fatty liver disease. PLoS One 2012; 7: e30668.
25. Gupte AA, Liu JZ, Ren Y, et al. Rosiglitazone attenuates age- and diet-associated nonalcoholic steatohepatitis in male low-density lipoprotein receptor knockout mice. Hepatology 2010; 52: 2001-2011.
26. Lalloyer F, Wouters K, Baron M, et al. Peroxisome proliferator-activated receptor-alpha gene level differently affects lipid metabolism and inflammation in apolipoprotein E2 knock-in mice. Arterioscler Thromb Vasc Biol 2011; 31: 1573-1579.
27. Zou Y, Du H, Yin M, et al. Effects of high dietary fat and cholesterol on expression of PPAR alpha, LXR alpha, and their responsive genes in the liver of apoE and LDLR double deficient mice. Mol Cell Biochem 2009; 323: 195-205.
28. Tanaka N, Moriya K, Kiyosawa K, et al. PPARalpha activation is essential for HCV core protein-induced hepatic steatosis and hepatocellular carcinoma in mice. J Clin Invest 2008; 118: 683-694.
29. Dorn C, Riener MO, Kirovski G, et al. Expression of fatty acid synthase in nonalcoholic fatty liver disease. Int J Clin Exp Pathol 2010; 3: 505-514.
30. Nagaoki Y, Hyogo H, Aikata H, et al. Recent trend of clinical features in patients with hepatocellular carcinoma. Hepatol Res 2012; 42: 368-375.
31. Cho ER, Shin A, Choi KS, et al. Factors associated with use of ultrasonography screening for hepatocellular carcinoma among hepatitis B or C carriers. Cancer Epidemiol 2010; 34: 713-716.
32. Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis 2001; 21: 3-16.
33. Li Z, Dranoff JA, Chan EP, et al. Transforming growth factor-beta and substrate stiffness regulate portal fibroblast activation in culture. Hepatology 2007; 46: 1246-1256.
34. Hill-Baskin AE, Markiewski MM, Buchner DA, et al. Diet-induced hepatocellular carcinoma in genetically predisposed mice. Hum Mol Genet 2009; 18: 2975-2988.
35. Kamata H, Honda S, Maeda S, et al. Reactive oxygen species promote TNFalpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell 2005; 120: 649-661.
36. Matsuda S, Kobayashi M, Kitagishi Y. Roles for PI3K/AKT/PTEN pathway in cell signaling of nonalcoholic fatty liver disease. ISRN Endocrinol 2013; 2013: 472432.
37. Elliott JC, Dover SD. Three-dimensional distribution of mineral in bone at a resolution of 15 micron determined by x-ray microtomography. Metab Bone Dis Relat Res 1984; 5: 219-221.
38. Savai R, Langheinrich AC, Schermuly RT, et al. Evaluation of angiogenesis using micro-computed tomography in a xenograft mouse model of lung cancer. Neoplasia 2009; 11: 48-56.